Advertisement
U.S. markets close in 44 minutes
  • S&P 500

    5,261.28
    +12.79 (+0.24%)
     
  • Dow 30

    39,838.81
    +78.73 (+0.20%)
     
  • Nasdaq

    16,400.86
    +1.34 (+0.01%)
     
  • Russell 2000

    2,124.94
    +10.59 (+0.50%)
     
  • Crude Oil

    83.06
    +1.71 (+2.10%)
     
  • Gold

    2,241.80
    +29.10 (+1.32%)
     
  • Silver

    24.97
    +0.22 (+0.88%)
     
  • EUR/USD

    1.0789
    -0.0041 (-0.38%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • GBP/USD

    1.2621
    -0.0017 (-0.13%)
     
  • USD/JPY

    151.4090
    +0.1630 (+0.11%)
     
  • Bitcoin USD

    70,735.05
    +2,100.84 (+3.06%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

The Gross Law Firm Announces Class Actions on Behalf of Shareholders of ZSAN, BRY and SPLK

NEW YORK, NY / ACCESSWIRE / December 15, 2020 / The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders in the following publicly traded companies. Shareholders who purchased shares in the following companies during the dates listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.

Zosano Pharma Corporation (NASDAQ:ZSAN)

Investors Affected : February 13, 2017 - September 30, 2020

A class action has commenced on behalf of certain shareholders in Zosano Pharma Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/zosano-pharma-corporation-loss-submission-form/?id=11584&from=1

Berry Corporation (NASDAQ:BRY)

Lawsuit on behalf of investors who purchased: (a) Berry common stock pursuant and/or traceable to the Company's initial public offering conducted on or about July 26, 2018; or (b) Berry securities between July 26, 2018 and November 3, 2020, both dates inclusive

A class action has commenced on behalf of certain shareholders in Berry Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Berry had materially overstated its operational efficiency and stability; (ii) Berry's operational inefficiency and instability would foreseeably necessitate operational improvements that would disrupt the Company's productivity and increase costs; (iii) the foregoing would foreseeably negatively impact the Company's revenues; and (iv) as a result, the Offering Documents and the Company's public statements were materially false and/or misleading and failed to state information required to be stated therein.

Shareholders may find more information at https://securitiesclasslaw.com/securities/berry-corporation-loss-submission-form/?id=11584&from=1

Splunk Inc. (NASDAQ:SPLK)

Investors Affected : October 21, 2020 - December 2, 2020

A class action has commenced on behalf of certain shareholders in Splunk Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://securitiesclasslaw.com/securities/splunk-inc-loss-submission-form/?id=11584&from=1

The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
The Gross Law Firm
15 West 38th Street, 12th floor
New York, NY, 10018
Email: dg@securitiesclasslaw.com
Phone: (212) 537-9430
Fax: (833) 862-7770

SOURCE: The Gross Law Firm



View source version on accesswire.com:
https://www.accesswire.com/620995/The-Gross-Law-Firm-Announces-Class-Actions-on-Behalf-of-Shareholders-of-ZSAN-BRY-and-SPLK

Advertisement